(Q36589849)

English

Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience

scientific article published on September 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Treatment of intermediate-risk prostate cancer with brachytherapy without supplemental pelvic radiotherapy: a review of the H. Lee Moffitt Cancer Center experience (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

author name string

Javier F Torres-Roca

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Alan B Cantor

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sonia Shukla

3

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Michael E Montejo

4

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Jay Friedland

5

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

John D Seigne

6

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Randy Heysek

7

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Julio Pow-Sang

8

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

384-390

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Extent of extracapsular extension in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Pathologic features from prostate needle biopsy and prognosis after I-125 brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Palladium-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: Importance of patient selection and implant quality

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Comparison of biochemical disease-free survival of patients with localized carcinoma of the prostate undergoing radical prostatectomy, transperineal ultrasound-guided radioactive seed implantation, or definitive external beam irradiation

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.12.003

7 January 2021

Identifiers

10.1016/J.UROLONC.2005.12.003

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36589849&oldid=1639463695"